We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mutations Force Proteins to Adopt Solid-like Structures

By LabMedica International staff writers
Posted on 31 Jan 2018
A recently published paper provided a unified structural view of self-assembly, aggregation, and interactions of the hnRNPA2 protein and the distinct effects of small chemical changes such as disease mutations and arginine methylation on these assemblies.

The hnRNPA2 protein is a component of RNA-processing organelles that lack membranes. More...
This protein forms inclusions when mutated in a syndrome characterized by the degeneration of neurons (bearing features of amyotrophic lateral sclerosis [ALS] and frontotemporal dementia), muscle, and bone.

In the January 18, 2018, online edition of the journal Molecular Cell investigators at Brown University (Providence, RI, USA) used nuclear magnetic resonance (NMR) spectroscopy, computer simulations, and microscopy to show how mutations and arginine methylation, a functional modification common to a large family of proteins with low-complexity domains, altered the formation low-complexity protein liquid droplets and their conversion to solid-like states in disease situations.

"We show how small chemical changes - involving only a few atoms - lead to big changes in assembly and disease-associated aggregation," said senior author Dr. Nicolas Fawzi, assistant professor of molecular pharmacology, physiology, and biotechnology at Brown University.

"These interactions are more dynamic and less specific than previously thought. A molecule does not take just one shape and bind to one shape but a molecule is flexible and interacts in flexible ways. Because these low-complexity domains are too flexible to be directly targeted by standard drugs, finding out how cells use and tame these domains is a potential route to stopping their unwanted assembly in disease."

Related Links:
Brown University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.